Optimal Adjuvant Therapy Selection for Chinese BRAF V600‐Mutant Stage III Melanoma: A Multicenter Efficacy Comparison of Targeted Agents, Immunotherapy, and Combinatorial Strategies

Documenti analoghi

• Addition of anti‐PD‐1 immunotherapy to BRAF inhibitor‐based targeted therapy improves real‐world survival and delays brain metastases in patients with BRAFV600‐mutant advanced melanoma: a multicenter cohort study
  di: Junwan Wu, et al.
  Pubblicazione: (2025)
• Transsulfuration Reprogramming: A Metabolic Driver of BRAF‐V600E Resistance in Melanoma
  di: Juntong Chen, et al.
  Pubblicazione: (2025)
• Hydrogels for Cancer Immunotherapy: Strategies From Construction to Application
  di: Xiaohua Chen, et al.
  Pubblicazione: (2026)
• Artificial Intelligence‐Based Multimodal Prediction of Postoperative Adjuvant Immunotherapy Benefit in Urothelial Carcinoma: Results From the Phase III, Multicenter, Randomized, IMvigor010 Trial
  di: Xiatong Huang, et al.
  Pubblicazione: (2025)
• A novel innate immunity‐mediated senescence mechanism regulated by cGAS–STING–IRF3–pRB
  di: Linbin Zhou, et al.
  Pubblicazione: (2025)